Journal
CHEMICAL COMMUNICATIONS
Volume 55, Issue 80, Pages 12016-12019Publisher
ROYAL SOC CHEMISTRY
DOI: 10.1039/c9cc03822a
Keywords
-
Categories
Ask authors/readers for more resources
Redox-modulating anticancer drugs allow the exploitation of altered redox biology observed in many cancer cells. We discovered dinuclear Rh-III(Cp*) and Ir-III(Cp*) complexes that have in vitro anticancer activity superior to cisplatin and the investigational drug IT-139, while being less toxic in haemolysis and in vivo zebrafish models. The mode of action appears to be related to DNA damage and ROS-mediated stress pathways.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available